"ErbB Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of structurally-related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS.
| Descriptor ID |
D066246
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009 D12.776.543.750.630.009 D12.776.543.750.750.400.074
|
| Concept/Terms |
ErbB Receptors- ErbB Receptors
- Receptors, ErbB
- Receptors, Epidermal Growth Factor-Urogastrone
- Receptors, Epidermal Growth Factor Urogastrone
- Receptors, Epidermal Growth Factor
- EGF Receptors
- Receptors, EGF
- Epidermal Growth Factor Receptor Family Proteins
- HER Family Receptors
- Family Receptors, HER
- Receptors, HER Family
- Erb-b2 Receptor Tyrosine Kinases
- Erb b2 Receptor Tyrosine Kinases
|
Below are MeSH descriptors whose meaning is more general than "ErbB Receptors".
Below are MeSH descriptors whose meaning is more specific than "ErbB Receptors".
This graph shows the total number of publications written about "ErbB Receptors" by people in this website by year, and whether "ErbB Receptors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 2 | 2 | 4 |
| 1998 | 0 | 1 | 1 |
| 2000 | 2 | 2 | 4 |
| 2001 | 1 | 1 | 2 |
| 2002 | 2 | 1 | 3 |
| 2003 | 3 | 1 | 4 |
| 2004 | 4 | 6 | 10 |
| 2005 | 2 | 4 | 6 |
| 2006 | 4 | 5 | 9 |
| 2007 | 9 | 1 | 10 |
| 2008 | 3 | 3 | 6 |
| 2009 | 1 | 5 | 6 |
| 2010 | 9 | 5 | 14 |
| 2011 | 5 | 8 | 13 |
| 2012 | 2 | 5 | 7 |
| 2013 | 6 | 0 | 6 |
| 2014 | 4 | 4 | 8 |
| 2015 | 7 | 4 | 11 |
| 2016 | 1 | 5 | 6 |
| 2017 | 2 | 3 | 5 |
| 2018 | 2 | 6 | 8 |
| 2019 | 1 | 8 | 9 |
| 2020 | 0 | 7 | 7 |
| 2021 | 2 | 3 | 5 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 2 | 4 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Comparative Single-Cell Analysis Reveals Tendon Progenitor Dysfunction by Age-Associated Oxidative Stress and Its Restoration by Antioxidant Treatments. J Cell Physiol. 2025 Feb; 240(2):e70016.
-
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers. Cancer Discov. 2025 Jan 13; 15(1):119-138.
-
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer. Pharmacoepidemiol Drug Saf. 2024 12; 33(12):e70049.
-
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A?Multi-Center Analysis and Literature Review. J Thorac Oncol. 2025 Apr; 20(4):465-474.
-
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Na?ve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol. 2025 Feb; 43(4):403-411.
-
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 10 01; 4(10):2823-2834.
-
A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies. Nat Cancer. 2024 Oct; 5(10):1579-1595.
-
Synergistic activation by Glass and Pointed promotes neuronal identity in the Drosophila eye disc. Nat Commun. 2024 Aug 17; 15(1):7091.
-
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clin Cancer Res. 2024 Aug 01; 30(15):3287-3297.
-
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. Nat Cancer. 2024 Aug; 5(8):1250-1266.